A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure

Summary

This is a phase II single-center study to evaluate the safety and effectiveness of vibecotamab, a CD3-CD123 bispecific antibody, in patients with acute myeloid leukemia with persistent or recurrent measurable residual disease and in patients with myelodysplastic syndrome that has not responded to or relapsed after conventional therapy

Timeline

Start

2022-05-06

Primary completion

2026-05-15

Completion

2026-05-15

Publications

• Short NJ, Bataller A, DiNardo CD, Montalban-Bravo G, Wang SA, Wang W, Maiti A, Nguyen D, Hachem MC, Bi TM, Issa GC, Chien KS, Ohanian M, Kadia TM, Loghavi S, Karrar O, Bachireddy P, Hwang H, Huang X, Garcia-Manero G, Ravandi F. Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study. J Hematol Oncol. 2026 Jun 27. doi: 10.1186/s13045-026-01825-3. Online ahead of print.

Drugs

Indications